首页> 美国卫生研究院文献>World Journal of Gastrointestinal Oncology >Patients with hematological malignancies and serological signs of prior resolved hepatitis B
【2h】

Patients with hematological malignancies and serological signs of prior resolved hepatitis B

机译:患有先前已解决的乙型肝炎的血液恶性肿瘤和血清学指标的患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Hepatitis B virus (HBV) infection affects a large part of the world population. Within the different virological HBV categories that have been identified, patients with occult HBV infection represent a peculiar group. These individuals harbor a replication competent virus, inhibited in its replicative function. Accordingly, cases of reactivations have been observed in immunosuppressed individuals who lose immunological control over the infection. Patients with hematological malignancies (HM) are treated with intense myelo- and immunosuppressive chemotherapy regimens which favor HBV reactivation. This event can have severe consequences, such as hepatitis flare, hepatic failure and even death. In addition, it can lead to delays or interruptions of curative treatments, resulting in a decreased disease free and overall survival. In this review, we will examine the event of HBV reactivation in patients with signs of resolved HBV infection undergoing treatment for HM and propose possible management strategies.
机译:乙型肝炎病毒(HBV)感染影响世界上很大一部分人口。在已确定的不同病毒学HBV类别中,隐匿性HBV感染的患者代表特殊人群。这些个体具有复制能力的病毒,其复制功能受到抑制。因此,已经在失去对感染的免疫控制的免疫抑制的个体中观察到重新激活的情况。患有血液恶性肿瘤(HM)的患者接受了强烈的骨髓和免疫抑制性化疗方案,这些方案有利于HBV激活。此事件可能会导致严重后果,例如肝炎发作,肝衰竭甚至死亡。另外,它可能导致治疗治疗的延迟或中断,从而导致无疾病和总体生存率下降。在这篇综述中,我们将检查接受HM治疗的已解决HBV感染征象的患者中HBV重新激活的事件,并提出可能的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号